Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity.

ABSTRACT:

Aims

Myocarditis is often associated with parvovirus B19 (B19V) persistence, which can induce vascular damage. Based on the antiviral and anti-inflammatory properties of telbivudine, we aimed to evaluate its efficacy to protect B19V-infected endothelial cells in vitro and to treat chronic lymphocytic myocarditis patients with B19V transcriptional activity.

Methods and results

We evaluated the endothelial-protective potential of telbivudine in human microvascular endothelial cells-1, which were infected with B19V. Treatment with 10 ng/mL of telbivudine decreased the B19V-induced endothelial cell apoptosis and endothelial-to-mesenchymal transition. Along with this finding, telbivudine reduced the expression of transforming growth factor-β1 and of tenascin-C. The endothelial-pr

SUBMITTER: Van Linthout S 

PROVIDER: S-EPMC6165949 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature